Skip to contentB
Bioadaptives, Inc.
B
BDPTBioadaptives, Inc. Q2 2026 · 10-Q
Revenue$4.99K$4.99K+55.0% vs Q2 2025 Net Income$150.09K$150.09KN/M vs Q2 2025 EPS Diluted$0.00$0.00N/M vs Q2 2025 Gross Profit$4,240+298.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR
Operating Cash Flowderived-$44,385N/M Margins · derivedGross margin85.0%+52.0 pt vs Q2 2025
Operating margin-3953.0%+4721.1 pt vs Q2 2025
Net margin3009.0%+7914.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 19, 2026 · 50 d after period end